scholarly journals Late results of a randomized trial on the role of mild hypofractionated radiotherapy for the treatment of localized prostate cancer

2020 ◽  
Vol 11 (5) ◽  
pp. 1008-1016
Author(s):  
Petros Alexidis ◽  
Sotirios Karatzoglou ◽  
Dimitris Dragoumis ◽  
Konstantinos Drevelegas ◽  
Ioannis Tzitzikas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Randomized Trial ◽  
Late Results ◽  
Localized Prostate Cancer ◽  
Hypofractionated Radiotherapy

scholarly journals The role of hypofractionated radiotherapy for the definitive treatment of localized prostate cancer: early results of a randomized trial

2019 ◽  
Vol 10 (25) ◽  
pp. 6217-6224
Author(s):  
Petros Alexidis ◽  
Dimitris Dragoumis ◽  
Sotirios Karatzoglou ◽  
Konstantinos Drevelegas ◽  
Ioannis Tzitzikas ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Randomized Trial ◽  
Localized Prostate Cancer ◽  
Hypofractionated Radiotherapy ◽  
Definitive Treatment ◽  
Early Results

scholarly journals Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Wei Guo ◽  
Yun-Chuan Sun ◽  
Jian-Qiang Bi ◽  
Xin-Ying He ◽  
Li Xiao
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Adverse Events ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Localized Prostate Cancer ◽  
Hypofractionated Radiotherapy ◽  
Cancer Specific Survival ◽  
Conventional Radiotherapy ◽  
Results Of Treatment

Abstract Background Prostate cancer is one of the most common cancers in the world. The results of treatment after hypofractionated radiotherapy only have been reported from several small randomized clinical trials. Therefore, we conducted a meta-analysis to compare clinical outcomes of hypofractionated radiotherapy versus conventional radiotherapy in the treatment of intermediate- to high-risk localized prostate cancer. Methods Relevant studies were identified through searching related databases till August 2018. Hazard ratio (HR) or risk ratio (RR) with its corresponding 95% confidence interval (CI) was used as pooled statistics for all analyses. Results The meta-analysis results showed that overall survival (HR = 1.12, 95% CI: 0.93–1.35, p = 0.219) and prostate cancer-specific survival (HR = 1.29, 95% CI: 0.42–3.95, p = 0.661) were similar in two groups. The pooled data showed that biochemical failure was RR = 0.90, 95% CI: 0.76–1.07, p = 0.248. The incidence of acute adverse gastrointestinal events (grade ≥ 2) was higher in the hypofractionated radiotherapy (RR = 1.70, 95% CI: 1.12–2.56, p = 0.012); conversely, for late grade ≥ 2 gastrointestinal adverse events, a significant increase in the conventional radiotherapy was found (RR = 0.75, 95% CI: 0.61–0.91, p = 0.003). Acute (RR = 1.01, 95% CI: 0.89–1.15, p = 0.894) and late (RR = 0.98, 95% CI: 0.86–1.10, p = 0.692) genitourinary adverse events (grade ≥ 2) were similar for both treatment groups. Conclusion Results suggest that the efficacy and risk for adverse events are comparable for hypofractionated radiotherapy and conventional radiotherapy in the treatment of intermediate- to high-risk localized prostate cancer.

Role of high-field MR in studies of localized prostate cancer

2013 ◽  
Vol 27 (1) ◽  
pp. 67-79 ◽  
Author(s):  
Miriam W. Lagemaat ◽  
Tom W. J. Scheenen
Keyword(s):  
Prostate Cancer ◽  
High Field ◽  
Localized Prostate Cancer ◽  
High Field Mr

scholarly journals PO-1124 A pilot study: Utilization of PROMs in hypofractionated radiotherapy for localized prostate cancer

2019 ◽  
Vol 133 ◽  
pp. S624
Author(s):  
K. Crowther ◽  
P. Shiels ◽  
A. Cole ◽  
P. Shepherd ◽  
S. Jain ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pilot Study ◽  
Localized Prostate Cancer ◽  
Hypofractionated Radiotherapy

scholarly journals Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer

2018 ◽  
Vol 36 (29) ◽  
pp. 2943-2949 ◽  
Author(s):  
Karen E. Hoffman ◽  
K. Ranh Voong ◽  
Lawrence B. Levy ◽  
Pamela K. Allen ◽  
Seungtaek Choi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Randomized Trial ◽  
Intensity Modulated Radiation Therapy ◽  
Cancer Control ◽  
Localized Prostate Cancer ◽  
Intensity Modulated ◽  
Genitourinary Toxicity ◽  
Gi Toxicity ◽  
Conventionally Fractionated

Purpose Hypofractionated radiotherapy delivers larger daily doses of radiation and may increase the biologically effective dose delivered to the prostate. We conducted a randomized trial testing the hypothesis that dose-escalated, moderately hypofractionated intensity-modulated radiation therapy (HIMRT) improves prostate cancer control compared with conventionally fractionated IMRT (CIMRT) for men with localized prostate cancer. Patients and Methods Men were randomly assigned to 75.6 Gy in 1.8-Gy fractions delivered over 8.4 weeks (CIMRT) or 72 Gy in 2.4 Gy fractions delivered over 6 weeks (HIMRT, biologically equivalent to 85 Gy in 1.8-Gy fractions assuming prostate cancer α-to-β ratio of 1.5). Failure was defined as prostate-specific antigen (PSA) failure (nadir plus 2 ng/mL) or initiation of salvage therapy. Modified Radiation Therapy Oncology Group criteria were used to grade late (≥ 90 days after completion of radiotherapy) GI and genitourinary toxicity. Results Most of the 206 men (72%) had cT1, Gleason score 6 or 7 (99%), and PSA level ≤ 10 ng/mL (90%) disease. Androgen deprivation therapy was received by 24%. With a median follow-up of 8.5 years, men treated with HIMRT experienced fewer treatment failures (n = 10) than men treated with CIMRT (n = 21; P = .036). The 8-year failure rate was 10.7% (95% CI, 5.8% to 19.1%) with HIMRT and 15.4% (95% CI, 9.1% to 25.4%) with CIMRT. There was no difference in overall survival ( P = .39). There was a nonsignificant increase in late grade 2 or 3 GI toxicity with HIMRT (8-year 5.0% v 12.6%; P = .08). However, GI toxicity was only 8.6% when rectal volume receiving 65 Gy of HIMRT was ≤ 15%. Late genitourinary toxicity was similar ( P = .84). There was no grade 4 toxicity. Conclusion The results of this randomized trial demonstrate superior cancer control for men with localized prostate cancer who receive dose-escalated moderately hypofractionation radiotherapy while shortening treatment duration.

Sign in / Sign up

Export Citation Format

Share Document